Swiss researchers may have finally found an effective second-line treatment for mesothelioma. Scientists with the Swiss Group for Clinical Cancer Research presented their findings at the recent European Society for Medical Oncology conference in Barcelona. Mesothelioma patients who fail after first-line therapy have few options. The new study focused on lurbinectedin, a drug that impacts cancer cells at the DNA level. Early studies suggest lurbinectedin might make a good second-line treatment for small cell lung cancer. According to the Swiss team, more than half of patients in their study responded to lurbinectedin as a second-line treatment for mesothelioma. In Search of a Second-Line Mesothelioma Treatment Malignant mesothelioma is notoriously difficult to diagnose and even harder to treat. It is usually … Continue reading Second-Line Treatment for Mesothelioma with Lurbinectedin
The powerful CRISPR gene editing technique might have a role to play in the future of mesothelioma treatment. CRISPR is a method for altering certain genes to help fight disease. This week, scientists at the University of Pennsylvania released data from the first study of CRISPR in US cancer patients. It was only a safety study, but the results are promising. They could have wide-ranging implications for patients fighting aggressive cancers like malignant mesothelioma. Modifying Genes To Help Fight Cancer The CRISPR gene editing technique is a simplified version of the method bacteria cells use to defend themselves against viruses. This antiviral defense system is called CRISPR-Cas9. The new Penn Medicine study involved just three cancer patients. Two of the … Continue reading CRISPR Gene Editing Technique and the Future of Mesothelioma Treatment
The findings of a new lung cancer study suggest that eating yogurt and fiber might help reduce mesothelioma risk. The study in JAMA Oncology involved more than 1.4 lung cancer patients from around the world. Researchers assessed the results of 10 dietary studies between 2017 and 2019. They found a “synergistic association” between eating fiber and yogurt and a lower risk of lung cancer. Pleural mesothelioma is a lung-related cancer with many of the same characteristics as lung cancer. It is possible that the same dietary habits might reduce mesothelioma risk, too. The Yin and Yang of an Anti-Cancer Diet The lung cancer researchers did not choose to study yogurt and fiber randomly. Dietary fiber is the main source of … Continue reading Can Yogurt and Fiber Reduce Mesothelioma Risk?
A new UK study points to some of the potential challenges and benefits for patients involved in mesothelioma clinical trials. Researchers at three teaching hospitals in England interviewed mesothelioma patients who took part in the Mesothelioma and Radical Surgery (MARS 2) trial. The trial compared outcomes in people who had a combination of surgery and chemotherapy with those who only had chemotherapy. The findings show that not all aspects of mesothelioma clinical trials are positive for patients. A Study Within a Study Pleural mesothelioma is a fast-growing cancer that starts on the lining around the lungs. Asbestos exposure is usually the cause. With standard cancer treatments, most mesothelioma patients face a poor prognosis. Mesothelioma often leads to death within a … Continue reading Mesothelioma Clinical Trials: Study Highlights Challenges for Patients
There has been a setback for researchers focused on the promise of pembrolizumab for mesothelioma. New research suggests that pembrolizumab (Keytruda) may not be the miracle mesothelioma drug that some were hoping for. The Phase III trial results were presented at a the European Society of Medical Oncology conference now underway in Spain. They suggest that pembrolizumab for mesothelioma may be no better than chemotherapy for improving survival. Pembrolizumab for Mesothelioma: How it Works Malignant pleural mesothelioma is a rare but lethal cancer. It is usually associated with on-the-job asbestos exposure. There is no cure. The only drug approved for mesothelioma treatment is Alimta (pemetrexed). Cancer researchers around the world are working hard to find other mesothelioma treatments. Pembrolizumab for … Continue reading Pembrolizumab for Mesothelioma Dealt Setback by New Trial Results
There is new evidence supporting the use of low-dose aspirin for cancer survival. The evidence comes from two new retrospective studies. The first involved patients with head and neck cancer. The second focused on patients with early-stage non-small cell lung cancer (NSCLC). NSCLC is similar to mesothelioma in many ways. Mesothelioma is an aggressive cancer that is often fatal within a year of diagnosis. Based on the new findings, some mesothelioma patients may consider talking to their doctors about aspirin for cancer survival Anti-Inflammatories and Cancer Treatment Anti-inflammatory drugs like aspirin can cut the risk for heart disease and heart attack. But research led by the Roswell Park Cancer Center shows they may have similar benefits for people with cancers … Continue reading Should Mesothelioma Patients Take Aspirin for Cancer Survival?
A new study out of Brazil suggests that many older mesothelioma patients may be at risk for malnutrition and the problems that go with it. The study included more than 4,500 Brazliian cancer patients from 45 hospitals. They were evaluated for their nutritional status, nutritional risk, and nutrition-related symptoms. Among the 25% of cancer patients over 65, more than half faced a moderate to severe risk for malnutrition. The findings suggest it is a problem hospitals should identify and address early for the best mesothelioma treatment outcomes. Mesothelioma and Nutritional Status As with other types of cancer, nutrition has an affect on the treatment of people with mesothelioma. An Australian study of pleural mesothelioma patients earlier this year found that … Continue reading Risk for Malnutrition Among Older Mesothelioma Patients
New data suggests first-line Keytruda treatment helps lung cancer patients more than chemotherapy – even if chemotherapy patients add Keytruda later. The news is likely to have implications for people with pleural mesothelioma, too. German researchers presented the data earlier this week at the World Lung Cancer Conference in Barcelona. The presentation was based on three years of the KEYNOTE-024 trial. The trial focused on lung cancer. But Keytruda is also an up-and-coming drug for malignant pleural mesothelioma. Pleural mesothelioma is a lung-related cancer similar to non-small cell lung cancer. Blocking PD-L1 with First-Line Keytruda Treatment Keytruda is the brand name for pembrolizumab. It is an immune checkpoint inhibitor that blocks a protein called PD-L1. To be eligible for first-line … Continue reading First-Line Keytruda Treatment May Support Longer Mesothelioma Survival
Mesothelioma patients and their doctors may have reason to be optimistic about a new lung cancer blood test. A random trial of more than 12,000 high-risk people in Scotland shows the EarlyCDT test combined with CT imaging can detect cancer early. Earlier diagnosis is likely to lead to longer survival of lung cancers like pleural mesothelioma. Researchers presented their findings on the new lung cancer blood test at a global conference this week in Spain. Largest Lung Cancer Trial As in the US, lung cancer is the biggest cancer killer in Scotland. Pleural mesothelioma is a form of lung cancer. Although it is rare, mesothelioma is more common in the UK than in other parts of the world. This is … Continue reading Lung Cancer Blood Test: Can it Find Early Mesothelioma?
A new report shows pleural mesothelioma rates in the US have failed to decline as they were predicted to do, but survival is improving slightly. The US government began to implement tighter restrictions on asbestos in the 1970s. Researchers at the Cleveland Clinic say original projections had the incidence of pleural mesothelioma peaking in the early 2000s as a result. Pleural mesothelioma rates were supposed to decline after that. But numbers from the National Cancer Database (NCDB) tell a different story. They suggest that, while mesothelioma survival is improving, incidence of asbestos cancer are not. Asbestos and Malignant Mesothelioma Malignant mesothelioma is the most serious of a range of illnesses caused by asbestos. Pleural mesothelioma is the most common type … Continue reading Pleural Mesothelioma Rates Remain Stagnant As Survival Improves